Zusammenfassung
Migräneattacken werden typischerweise von vegetativen Begleiterscheinungen wie Übelkeit und Erbrechen begleitet. Dabei kommt es zu einer Verringerung der Peristaltik, so daβ oral eingenommene Medikamente nur verzögert ins Duodenum und in tiefere Dünndarmabschnitte transportiert werden, wo sie dann auch verzögert resorbiert werden. Die Wirksamkeit oral eingenommener Medikamente, seien es Analgetika oder spezifische Migränemittel, hängt aber überwiegend von der Zeit ab, bis die maximale Konzentration im Serum erreicht wird. Dies erklärt, warum häufig Analgetika —allein eingenommen — nicht ausreichend wirksam sind.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Andersson PG, Hinge HH, Johansen O, Andersen CU, Lademann A, Gotzsche PC (1989) Double-blind study of naproxen vs placebo in the treatment of acute migraine attacks. Cephalalgia 9:29–32
Bannwarth B, Demotes-Mainard F, Schaeverbeke T, Labat L, Dehais J (1995) Central analgesic effects of aspirin-like drugs. Fund Clin Pharmacol 9:1–7
Bates D, Ashford E, Dawson R, Ensink F-BM, Gilhus NE, Olesen J, Pilgrim AJ, Shevlin P (1994) Subcutaneous sumatriptan during the migraine aura. Neurology 44:1587–1592
Becker WJ, on behalf of the Study Group (1995) A placebo-controlled, dose-defining study of sumatriptan nasal spray in the acute treatment of migraine. Cephalagia 15 (Suppl 14): 239
Brown EG, Endersby CA, Smith RN, Talbot JCC (1991) The safety and tolerability of sumatriptan: an overview. Eur Neurol 31:339–344
Brune K, Beck WS, Geisslinger G, Menzel-Soglowek S, Peskar BM, Peskar BA (1991) Aspirin-like drugs may block pain independently of prostaglandin synthesis inhibition. Experientia 47:257–261
Buzzi G, Moskowitz MA (1990) The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 99:202–206
Buzzi G, Sakas DE, Moskowitz MA (1989) Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol 165:251–258
Buzzi MG, Carter WB, Shimizu THH, Moskowitz MA (1991) Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 30:1193–1200
Buzzi MG, Moskowitz MA (1991) Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia 11:165–168
Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H (1991) Treatment of acute migraine with subcutaneous sumatriptan. JAMA 265:2831–2835
Chabriat H, Danchot J, Grippon P, Bousser MG (1994) Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo-controlled study. Cephalalgia 14:297–300
Connor HE, Fenjuk W, Beattie DT (1998) Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia im Druck
Cumberbatch MJ, Hill RG, Hargreaves RJ (1997) Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol 328:37–40
Dahlöf C (1993) Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. Cephalalgia 13:166–171
Dichgans J, Diener HC, Gerber WD, Verspohl EJ, Kukiolka H, Kluck M (1984) Analgetika-induzierter Dauerkopfschmerz. Dtsch med Wschr 109:369–373
Diener HC, Klein KB (1996) The first comparison of the efficacy and safety of 311C90 and sumatriptan in the treatment of migraine. Poster, 3rd European Headache Conference, Sardinia
Dixon R, Gillotin C, Gibbens M, Posner J, Peck RW (1997a) The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers. Br J Clin Pharmacol 3:273–281
Dixon R, Warrander A (1997) The clinical pharmacokinetics of zolmitriptan. Cephalalgia 17:15–20
Dixon RM, Meire HB, Evans DH, Watt H, On N, Posner J, Rolan PE (1997b) Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers. Cephalalgia 17:639–646
Dowson AJ, on behalf of the Study Group (1996) An open, dose-titration study evaluating 25 mg, 50 mg and 100 mg doses of oral sumatriptan in the acute treatment of migraine. Poster, 2nd EFNS Congress, Rome
Earl NL (1997) Zolmitriptan (311C90), a new acute treatment for migraine: an overview of safety. In: Oleson J, Tfelt-Hansen P (Hrsg.) Frontiers of Headache Research. Headache Treatment: Trial Methodology and New Drugs. Lippin-cott-Raven, New York, 267–272
Edmeads JG, Millson DS (1997) Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5-HT1B/1D agonist. Cephalalgia 17:41–52
Feniuk W, Humphrey PPA, Perren M (1989) The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetized dogs. Brit J Pharmacol 96:83–90
Ferrari MD (1996) The clinical effectiveness of 311C90 in the acute treatment of migraine. Eur Neurol 36 (Suppl 2):4–7
Ferrari MD (1997) 311C90: Increasing the options for the therapy with effective acute antimigraine 5-HT1B/D receptor agonists. Neurology 48 (Suppl 3):21–24
Gijsman H, Kramer MS, Sargent J, Tuchman M, Matzura-Wolfe D, Polis A, Teall J, Block G, Ferrari MD (1997) Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia 17:647–651
Goadsby PJ, Edvinsson L (1994) Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache 34: 394–399
Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28:183–187
Goadsby PJ, Gundlach AL (1991) Localization of 3H-Dihydroergotamine-binding sites in the cat central nervous system: relevance to migraine. Ann Neurol 29:91–94
Goadsby PJ, Hoskin KJ (1996) Inhibition of trigeminal neurons by intravenous administration of the serotonin (5-HT)lB/D receptor agonist zolmitriptan (311C90): Are brain stem sites therapeutic target in migraine? Pain 67:355–359
Goadsby PJ, Knight Y (1997) Inhibition of trigeminal neurones after intravenous administration of naratriptan trough an action at 5-hydroxytryptamine (5-HT1B/1D) receptors. Br J Pharmacol 122:918–922
Göbel H, Boswell D, Winter PDO, Crisp A (1997) A comparison of the efficacy and tolerability of naratriptan and sumatriptan among migraineurs with a history of frequent (50% of attacks) headache recurrence. Poster, VIIIth IHS Congress, Amsterdam.
Göbel H, Ernst M, Jeschke J, Keil R, Weigle L (1992) Acetylsalicylic acid activates antinociceptive brain-stem reflex activity in headache patients and in healthy subjects. Pain 48:187–195
Gross MLP, Kay J, Turner AM, Jewsbury J, Cleal AL (1995) Long-term efficacy of subcutaneous sumatriptan using a novel self-injector. Headache 35:601–606
Hämäläinen ML, Hoppu K, Santavuori P (1997) Sumatriptan for migraine attacks in children: A randomized placebo-controlled study. Do children with migraine attacks respond to oral sumatriptan differently from adults? Neurology 48:1100–1103
Havanka-Kanniainen H (1989) Treatment of acute migraine attack: ibuprofen and placebo compared. Headache 29:507–509
Humphrey PPA, Feniuk W, Motevalian M, Parsons A A, Whalley ET (1991) The vasoconstrictor action of sumatriptan on human isolated dura mater. In: Fozard JR, Saxena PR (Hrsg.) Serotonin: molecular biology, receptors and functional effects. Birkhäuser, Basel, 420–429
Johnson ES, Ratcliffe DM, Wilkinson M (1985) Naproxen sodium in the treatment of migraine. Cephalalgia 5:5–10
Kaube H, Hoskin KL, Goadsby PJ (1993) Intravenous acetylsalicylic acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal cord in the cat. Headache 33:541–544
Kaube H, Hoskin KL, Goadsby PJ (1993) Sumatriptan inhibits central trigeminal neurons only after blood-brain barrier disruption. Cephalalgia 13 (Suppl 13):41
Kaube H, May A, Diener HC, Pfaffenrath V (1994) Sumatriptan. BMJ 308:1573
Kirch W, Ziegler A (1989) Pharmakologische Grundlagen der Anwendung von Dihydroergotamin. Neurologie Psychiatrie 2:43–48
Klassen A, Elkind A AM, Webster C, Laurenza A, on behalf of the Naratriptan S2WA3001 Study Group (1997) Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Headache 37:630–645
Klassen AC, Gabriel H, Hobbs S, Woessner M (1995) Safety and efficacy of sumatriptan suppositories in the acute treatment of migraine attacks. Poster, VII. IHS Congress, Toronto
Kunka RL, Hussey EK, Shaw S, Warner P, Aubert B, Richard I, Fowler PA, Pakes GE (1997) Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers. Cephalalgia 17:532–540
Lipton RB, Stewart WF (1997) Clinical applications of zolmitriptan (Zomig, 311C90). Cephalalgia 17 (Suppl 18):53–59
Longmore J, Hargreaves RJ, Boulanger CM, Brown MJ, Desta B, Ferro A, Schofield WN, Taylor AA, Hill RG (1997) Comparison of the vasoconstrictor properties of the 5-HT1D-receptor agonists rizatriptan (MK-462) and sumatriptan in human isolated coronary artery: outcome of two independent studies using different experimental protocols. Funct Neurol 12:3–9
MacGregor EA, Wilkinson M, Bancroft K (1993) Domperidone plus paracetamol in the treatment of migraine. Cephalalgia 13:124–127
Maclntyre PD, Bhargava B, hogg KJ, Gemmili JD, Hillis WS (1993) Effect of subcutaneous sumatriptan, a selective 5-HT1 agonist, on the systemic, pulmonary and coronary circulation. Circulation 87:401–405
Martin G, Dixon R, Seaber E (1997) Preclinical and clinical pharmacology of Zolmitriptan (311C90): A novel antimigraine agent. In: Oleson J, Tfelt-Han-sen P (Hrsg.) Headache Treatment: Trial Methodology and New Drugs. Lippincott-Raven, New York, 257–262
Martin GR (1996) Inhibition of the trigemino-vascular system with 5-HT1D agonist drugs: Selectively targeting additional sites of action. Eur.Neurol 36 (Suppl 2):13–18
Martin GR, Robertson AD, MacLennan SJ, Prentice DJ, Barret VJ, Buckingham J, Honey AC, Giles H, Moncada S (1997) Receptor specificity and trigeminovascular inhibitory actions of a novel 5-HT(lB/lD) receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol 2:157–164
Massiou H, on behalf of the Study Group (1996) A comparison of sumatriptan nasal spray 20 mg and intranasal dihydroergotamin in the acute treatment of migraine. Poster, 3rd European Headache Conference, Sardinia
Mathew NT, Asgharnejad M, Peykamian M, Laurenza A, on behalf of the Naratriptan S2WA3003 Study Group (1997) Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. Neurology 49:1485–1490
Monstadt I, on behalf of the Study Group (1995) The long-term tolerability, safety and efficacy of 25 mg sumatriptan suppositories in the acute treatment of migraine. Poster, VII. IHS Congress, Toronto
Nebe J, Heier M, Diener HC (1995) Low-dose ibuprofen in self-medication of mild to moderate headache: a comparison with acetylsalicylic acid and placebo. Cephalalgia 15:531–535
O’Callaghan J, for the Study Group (1993) Long-term efficacy of subcutaneous sumatriptan using a novel self-injector. Cephalalgia 13 (Suppl 13): 161
Parsons AA, Whalley ET, Feniuk W, Connor HE, Hunmphrey PPA (1989) 5-HT1-like receptors mediate 5-hydroxytryptamine-induced contraction of human isolated basilar artery. Brit J Pharmacol 96:434–449
Patten JP (1991) Clinical experience with oral sumatriptan: a placebo-controlled, dose-ranging study. J Neurol 238 (Suppl 1):S62–S65
Pearce I, Frank GJ, Pearce JMS (1983) Ibuprofen compared with paracetamol in migraine. Practitioner 227:465–467
Pfaffenrath V on behalf of the Study Group (1996) A study comparing the efficacy, safety, and tolerability of oral sumatriptan 25 mg, 50 mg and 100 mg doses in the acute treatment of migraine. Poster, 2nd EFNS Congress, Rome
Pilgrim AJ, Blakeborough P (1994) The clinical efficacy of sumatriptan in the acute treatment of migraine. Rev Contemp Pharmacother 5: 95–309
Rapoport AM, Ramadan NM, Adelmann JU, Mathew NT, Elkind AH, Kudrow DB, Earl NL, on behalf of the 017 Clinical Trial Study Group (1997) Optimizing the dose of zolmitriptan (Zomig 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose-finding study. Neurology 49:1210–1218
Rolan P (1997) Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90). Cephalalgia 17:21–27
Rosenkranz S, Deutsch HJ, Erdmann E (1997) “Saint Anthony’s Fire”: Ergotamin-induzierte Gefäβspasmen als Ursache akuter ischämischer Syndrome. Dtsch Med Wochenschr 14:450–454
Ross-Lee LM, Eadie MJ, Heazlewood V, Bochner F, Tyrer JH (1983) Aspirin pharmacokinetics in migraine. The effect of metoclopramide. Eur J Clin Pharmacol 24:777–785
Ryan R, Elkind A, Baker CC, Mullican W, DeBussy S, Asgharnejad M (1997) Sumatriptan nasal spray for the acute treatment of migraine. Neurology 49:1225–1230
Saito K, Markowitz S, Moskowitz MA (1988) Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches. Ann Neurol 24:732–737
Salonen R on behalf of the Study Group (1996) Patient preference among 25 mg, 50 mg and 100 mg oral doses of sumatriptan. Poster, 2nd EFNS Congress, Rome
Salonen R, Ashford E, Dahlöf C, Dawson R, Gilhus NE, Lüben V, Noronha D, Warter J, for the International Study Group (1994) Intranasal sumatriptan for the acute treatment of migraine. J Neurol 241:463–469
Schoenen J, Sawyer J (1997) Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy. Cephalalgia 17 Suppl 18:28–40
Sciberras DG, Polvino WJ, Gertz BJ, Cheng H, Stepanavage M, Wittreich J, Olah T, Edwards M, Mant T (1997) Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist. Br J Clin Pharmacol 43:49–54
Seaber E, On N, Dixon RM, Gibbens M, Leavens WJ, Liptrot J, Chittick G, Posner J, Rolant PE, Peck RW (1997) The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). Br J Clin Pharmacol 43:579–587
Shepheard SL, Williamson DJ, Beer MS, Hill RG, Hargreaves RJ (1997) Differential effects of 5-HT1B/D receptor agonists on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats. Neuropharmacology 36:525–533
Solomon GD, Cade RK, Klapper JA, Earl NL, Saper JR, Ramadan NM, on behalf of the 042 Clinical Trial Study Group (1997) Clinical efficacy and tolerability of 2,5 mg zolmitriptan for the acute treatment of migraine. Neurology 49:1219–1225
Tansey MJB, Pilgrim AJ, Lloyd K (1993) Sumatriptan in acute treatment of migraine. J Neurol Sci 114:109–116
Tfelt-Hansen P, Henry P, Mulder LJ, Schaeldewaert RG, Schoenen J, Chazot G (1995) The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 346:923–926
Tfelt-Hansen P, Olesen J (1984) Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: a double-blind study. Cephalalgia 4:107–111
The Multinational Oral Sumatriptan and Cafergot Comparative Study Group (1991) A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. Eur Neurol 31:314–322
The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group (1992) A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol 32:177–184
The Oral Sumatriptan Dose-Defining Study Group (1991) Sumatriptan — an oral dose- defining study. Eur Neurol 31:300–305
The Oral Sumatriptan International Multiple-Dose Study Group (1991) Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol 31:306–313
The Subcutaneous Sumatriptan International Study Group (1991) Treatment of migraine attacks with sumatriptan. N Engl J Med 325:316–321
The Sumatriptan Auto-Injector Study Group (1991) Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. Eur Neurol 31:323–331
Touchon J, Bertin L, Pilgrim AJ, Ashford E, Bès A (1996) A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology 47:361–365
Visser (1997) Pharmacologic profile and clinical efficacy of rizatriptan. Vortrag VIII. IHS Congress, Amsterdam
Visser WH, for the Study Group (1993) Does a combined regimen of subcutaneous followed by oral sumatriptan prevent headache recurrence. Cephalalgia 13, Suppl. 13:189
Visser WH, Jaspers NMWH, de Vriend RHM, Ferrari MD (1996) Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 16:264–269
Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari MD, for the Dutch/US Rizatriptan Study Group (1997) Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Arch Neurol 53:1132–1137
Volans GN (1975) The effect of metoclopramide on the absorption of effervescent aspirin in migraine. Br J Clin Pharmacol 2:57–63
Weiller C, May A, Limmroth V, Jüptner M, Kaube H, van Schayck R, Coenen HH, Diener HC (1995) Brain stem activation in spontaneous human migraine attacks. Nature Medicine 1:658–660
Wilkinson M, Pfaffenrath V, Schoenen J, Diener HC, Steiner T (1995) Migraine and cluster headache — their management with sumatriptan: a critical rewiew of the current clinical experience. Cephalalgia 15:337–357
Williamsen DJ, Shepheard SL, Hill RG, Hargreaves RJ (1997) The novel anti-migraine agent rizatriptan inhibtis neurogenic durai vasodilation and extravasation. Eur J Pharmacol 328:61–64
Zagami AS, for the 311C90 Long-Term Study Group (1997) 311C90: long-term efficacy and tolerability profile for the acute treatment of migraine. Neurology 48 (Suppl 3):S25–S28
Zschiedrich M, Heidrich H, Dienes HP (1985) Ergotismus: Epidemiologie, Pathogenese, Histomorphologie, Diagnostik und Therapie. Med Klinik 80:721–727
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Diener, HC. (1999). Akuttherapie der Migräneattacke. In: Migräne. Optimierte Arzneimitteltherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59858-6_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-59858-6_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-63950-3
Online ISBN: 978-3-642-59858-6
eBook Packages: Springer Book Archive